%0 Journal Article
%A Stoian, Raluca
%A Erbes, Thalia
%A Zamboglou, Constantinos
%A Scholber, Jutta
%A Gainey, Mark
%A Sachpazidis, Ilias
%A Haehl, Erik
%A Spohn, Simon K B
%A Verma, Vivek
%A Krug, David
%A Rühle, Alexander
%A Juhasz-Böss, Ingolf
%A Grosu, Anca-Ligia
%A Nicolay, Nils H
%A Sprave, Tanja
%T Intraoperative radiotherapy boost as part of breast-conservation therapy for breast cancer: a single-institution retrospective analysis.
%J Strahlentherapie und Onkologie
%V 197
%N 9
%@ 1439-099X
%C Heidelberg
%I Springer Medizin
%M DKFZ-2021-01011
%P 812-819
%D 2021
%Z  2021 Sep;197(9):812-819
%X There are currently no data from randomized controlled trials on the use of intraoperative radiotherapy (IORT) as a tumor bed boost as part of a breast-conservation approach for breast cancer. This study retrospectively reviewed the safety and efficacy of IORT as a boost treatment at a tertiary cancer center.From 2015 to 2019, patients underwent breast-conserving surgery with axillary lymph node staging and a single dose of 20 Gy IORT with 50-kV photons, followed by whole-breast irradiation (WBI) and adjuvant systemic therapy (if applicable). Patients were followed for assessment of acute and late toxicities (using the Common Terminology Criteria for Adverse Events version 5.0) at 3-6-month intervals. Outcomes included ipsilateral (IBTR) and contralateral breast progression-free survival (CBE), distant metastasis-free survival (DMFS), and overall survival (OS).Median follow-up for the 214 patients was 28 (range 2-59) months. Most patients had T1 disease (n = 124) and were clinically node negative. Only few patients had high-grade and/or triple-negative disease. The vast majority of patients underwent sentinel node biopsy, and 32 (15
%K Adjuvant radiation therapy (Other)
%K Boost (Other)
%K Breast-conservation therapy (Other)
%K Early breast cancer (Other)
%K Intraoperative radiotherapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:33938966
%R 10.1007/s00066-021-01785-2
%U https://inrepo02.dkfz.de/record/168703